Tagged with Merck

Spain Marieta Jiménez, president and general manager of Merck Spain, highlights her three top priorities: innovation, science and technology, and women’s equality. Furthermore, she gives an overview of the need for better collaboration for long-term sustainably of the Spanish healthcare system and breaks down the role of the ClosingGap cluster to…

Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria.   From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…

China Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory changes on the Biopharma business of Merck KGaA, Darmstadt, Germany in China; the significance of the affiliate’s commercial growth as…

Korea Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for companies like Merck to utilize local partnerships.   We are in the process of preparing launches of our new molecules…

Hong Kong Merck Hong Kong’s Hee-sun Lee gives her first impressions of the Hong Kong market, her main priorities, upcoming product launches and tapping into the territory’s R&D ecosystem. Hee-sun, having joined Merck Pharmaceutical Hong Kong in February 2018 from the South Korean affiliate, what are your first impressions of the market…

Portugal Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s global vision, new and exciting products coming soon to the Portuguese market and the importance of collaborative partnerships across the…

Canada At the 350th anniversary of the company, Gaby Murphy, EMD Serono’s managing director, gives an insight into the turning point for the affiliate in 2017 with three new Health Canada approvals. Over the last few months, we have witnessed significant changes within the Canadian pharmaceutical landscape, especially in terms of…

Baltics Evija Buksa, general manager at Merck in Latvia, explains the strong history of Merck in the country as well as its key role in participating in the discussions to shape the Latvian healthcare system. Could you please start by introducing Merck in Latvia and the strategic significance of the local…

Pharma The top 10 pharmaceutical companies in Canada for 2016 in terms of total sales and market share. Johnson & Johnson leads the way with USD 2.93 billion in sales, followed by Novartis with USD 1.24 billion and TEVA with USD 1.19 billion.

Merck Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal with NHS England for its innovative new multiple sclerosis (MS) treatment, Mavenclad and how this deal stands as a new…

Canada Chirfi Guindo, president and managing director of Merck Canada, highlights the stunning transformation that has led to a revitalized new Merck affiliate, the innovation opportunities Canada’s fragmented and diverse health systems offers, and the importance of greater collaboration and dialogue between all stakeholders within Canada’s healthcare and innovation ecosystem. Three…

Bulgaria Ana Tsakova, managing director at Merck Bulgaria, emphasizes the duty of the industry to raise the bar of treatment quality in the country and shows the commitment of Merck in this regard to collaborate with both physicians and patients in key therapeutic areas such as oncology, fertility, multiple sclerosis, diabetes,…